CD4 and infection: Furthermore, adjusted through gender, age, marital status, education, occupation, infection route, pre-treatment CD4 T cell counts, pre-treatment Viral load, clinical stage, drug resistance, treatment regimen, duration time for initiated treatment, and treatment time, the result revealed significant differences between CRF01_AE (reference), CRF07_BC (AHR=0.46), CRF08_BC (AHR=0.68), CRF55_01B (AHR=0.4), and other subtypes (AHR=0.2) (Figure 3B).